Document

Exams Committee Chair Role Description. Published July 2023. 

Published July 2023. 

This programme has been developed by leading experts, focused on practical tips and take-home messages. Disclaimer: the programme content is accurate at the time of publishing and may be updated. Published July 2023.

This update of the 2010 Contraception for Women Aged Over 40 Years guideline has been developed by the FSRH and brings together evidence and expert opinion on contraception for women aged over 40 years. The guideline was developed with a team of experts in the relevant fields and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings. 

The guideline provides evidence-based recommendations and good practice points to enable clinicians to support individuals to make informed decisions about choosing and using IUC. It includes information on assessing suitability of IUC use for contraception, the risks and benefits of IUC and guidance for IUC procedures, complications and follow-up. Published March 2023.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

The digital version can be accessed from the BMJ SRH website: FSRH Guideline (March 2023) Intrauterine contraception BMJ Sexual & Reproductive Health 2023;49:1-142. 

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on progestogen-only contraceptive pills. Please refer to the full 2022 FSRH Progestogen-only Pills Clinical Guideline for further information and supporting evidence for this advice. This document is written for FSRH members and requires you to log in to access it.

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any health care professional or health service providing contraceptive care in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

Also available in digital format on the BMJ website: FSRH Guideline (August 2022) Progestogen-only Pills. BMJ Sexual & Reproductive Health 2022; 48:Suppl 1.

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

The digital version can be accessed from the BMJ SRH website: FSRH Guideline (February 2021) Progestogen-only Implant. BMJ Sexual & Reproductive Health 2021; 47:Suppl 1. 

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any healthcare professional or health service providing contraceptive care in the UK. In this version of the POP Guideline, the supporting evidence for the recommendations has been removed from the main text and located in an appendix for ease of reading. This document is available to FSRH members and candidates only. 

Summary of the All Party Parliamentary Group on Sexual and Reproductive Health in the UK's AGM and meeting on 4 July 2023.